NCCN Guidelines Updates: Pancreatic Cancer

Author:
Margaret A. Tempero
Search for other papers by Margaret A. Tempero in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 17: Issue 5.5
Online Publication Date:
May 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5007
Restricted access

Outcomes for pancreatic cancer are becoming less discouraging with the refinement of molecular profiling, both germline and somatic, and beneficial effects seen with adjuvant chemotherapy. The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.

Correspondence: Margaret A. Tempero, MD, UCSF Helen Diller Family Comprehensive Cancer Center, 550 16th Street, 6th Floor, Box 3211, San Francisco, CA 94143. Email: margaret.tempero@ucsf.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Mandelker D, Zhang L, Kemel Y, et al.. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 2017;318:825–835.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Le DT, Uram JN, Wang H, et al.. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  • 3.

    Le DT, Durham JN, Smith KN, et al.. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–413.

  • 4.

    Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

  • 5.

    Conroy T, Hammet P, Hebbar M, et al.. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine in patients with resected pancreatic ductal adenocarcinomas [abstract]. J Clin Oncol 2018;36(Suppl):Abstract LBA4001.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2019
Online Publication Date:
May 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 23660 2404 178
PDF Downloads 15435 1886 143
EPUB Downloads 0 0 0